Investigational Drug Information for GLPG1690
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for GLPG1690?
GLPG1690 is an investigational drug.
There have been 9 clinical trials for GLPG1690.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 5th 2018.
The most common disease conditions in clinical trials are Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, and Fibrosis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are five US patents protecting this investigational drug and fifty-three international patents.
Summary for GLPG1690
| US Patents | 5 |
| International Patents | 53 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2018-11-05) |
| Vendors | 28 |
Recent Clinical Trials for GLPG1690
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis | Galapagos NV | Phase 2 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis | Galapagos NV | Phase 2 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care | Galapagos NV | Phase 3 |
Clinical Trial Summary for GLPG1690
Top disease conditions for GLPG1690
Top clinical trial sponsors for GLPG1690
US Patents for GLPG1690
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG1690 | See Plans and Pricing | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | See Plans and Pricing |
| GLPG1690 | See Plans and Pricing | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | See Plans and Pricing |
| GLPG1690 | See Plans and Pricing | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| GLPG1690 | See Plans and Pricing | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG1690
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG1690 | Argentina | AR095280 | 2033-03-14 | See Plans and Pricing |
| GLPG1690 | Australia | AU2014231009 | 2033-03-14 | See Plans and Pricing |
| GLPG1690 | Australia | AU2017286828 | 2033-03-14 | See Plans and Pricing |
| GLPG1690 | Australia | AU2019204539 | 2033-03-14 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
